Biomarkers for Alzheimer's disease begin to change many years before symptoms present and a diagnosis is made.
Shuheng Wang and Bote Zhao worked on a long term study tracking these changes. The team took samples from participants' cerebrospinal fluid, imaged their brain and carried out cognitive assessments over a 20 year period. They found one biomarker (amyloid-beta 42) began to differ, compared to participants who didn't go on to develop the disease, 18 years prior to diagnosis and many others would deviate in the years preceding. It's hoped these findings will lead to early diagnosis and intervention for those with Alzheimer's disease.
Alzheimer's disease is an incurable neurodegeneration disease
which could affect cognitive function and daily living mostly in older people.
Wang Shuheng and Zhao Boitu are part of a team of researchers looking at how biomarkers change
over the years preceding an Alzheimer's disease diagnosis.
We found that the biomarker can change about 90 years before the symptoms onset.
For me, my experience, my aim to join in the journey of Alzheimer's was really personal,
just rooted in my experience with my grandfather.
He was a very hardworking man and a kind man, but seven years ago he was diagnosed with dementia.
Just caring for my grandfather made me realize that just how devastating it can be,
not just for the patients but for everyone around them.
When we talk about biomarkers in Alzheimer's disease, we are referring to a set of key
indicators that reflect specific biological states or pathological changes.
The team tracked AD, or Alzheimer's disease, biomarkers over the 20 years,
including measuring proteins in the cerebral spinal fluid and tracking the volume of the
hippocampus, which is associated with memory loss in Alzheimer's disease.
In terms of methodology, the uniqueness and the value of this research lie in the study design,
long-term follow-up, and high-quality sample.
This study was conducted with a long follow-up period of 20 years
to thoroughly trace the trajectories of AD biomarkers before AD diagnosis.
A number of biomarkers were shown to change in the years before diagnosis.
The hippocampus began to show signs of deterioration
eight years before participants were diagnosed with AD.
And when looking at amyloid beta-42, a protein that aggregates in the brain
of people with Alzheimer's disease, leading to reduced levels in the CSF,
a change was observed 18 years prior to onset.
Our study has some important clinical implications.
The major one is for the early diagnosis and intervention.
We found that even before symptoms appear, biomarkers are already starting to change.
This suggests that in the future, we could use fluid-based
tests to identify the at-risk individuals much earlier.
Overall, this finding gives us a better understanding of the disease progression
and offers valuable insights for future clinical research.